Cargando…

Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11

INTRODUCTION: Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of new psychoactive substances that have been associated with multiple instances and types of toxicity. Some SCRAs appear to carry a greater toxicological burden than others, or compared to the prototypical cannabis-de...

Descripción completa

Detalles Bibliográficos
Autores principales: Kevin, Richard C., Cairns, Elizabeth A., Boyd, Rochelle, Arnold, Jonathon C., Bowen, Michael T., McGregor, Iain S., Banister, Samuel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798004/
https://www.ncbi.nlm.nih.gov/pubmed/36590635
http://dx.doi.org/10.3389/fpsyt.2022.1048836
_version_ 1784860811076829184
author Kevin, Richard C.
Cairns, Elizabeth A.
Boyd, Rochelle
Arnold, Jonathon C.
Bowen, Michael T.
McGregor, Iain S.
Banister, Samuel D.
author_facet Kevin, Richard C.
Cairns, Elizabeth A.
Boyd, Rochelle
Arnold, Jonathon C.
Bowen, Michael T.
McGregor, Iain S.
Banister, Samuel D.
author_sort Kevin, Richard C.
collection PubMed
description INTRODUCTION: Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of new psychoactive substances that have been associated with multiple instances and types of toxicity. Some SCRAs appear to carry a greater toxicological burden than others, or compared to the prototypical cannabis-derived agonist Δ(9)-tetrahydrocannabinol (Δ(9)-THC), despite a common primary mechanism of action via cannabinoid 1 (CB1) receptors. “Off-target” (i.e., non-CB1 receptor) effects could underpin this differential toxicity, although there are limited data around the activity of SCRAs at such targets. METHODS: A selection of 7 SCRAs (AMB-FUBINACA, XLR11, PB-22, AKB-48, AB-CHMINICA, CUMYL-PINACA, and 4F-MDMB-BUTINACA), representing several distinct chemotypes and toxicological profiles, underwent a 30 μM single-point screen against 241 G protein-coupled receptor (GPCR) targets in antagonist and agonist mode using a cellular β-arrestin recruitment assay. Strong screening “hits” at specific GPCRs were followed up in detail using concentration-response assays with AMB-FUBINACA, a SCRA with a particularly notable history of toxicological liability. RESULTS: The single-point screen yielded few hits in agonist mode for any compound aside from CB1 and CB2 receptors, but many hits in antagonist mode, including a range of chemokine receptors, the oxytocin receptor, and histamine receptors. Concentration-response experiments showed that AMB-FUBINACA inhibited most off-targets only at the highest 30 μM concentration, with inhibition of only a small subset of targets, including H(1) histamine and α(2B) adrenergic receptors, at lower concentrations (≥1 μM). AMB-FUBINACA also produced concentration-dependent CB1 receptor signaling disruption at concentrations higher than 1 μM, but did not produce overt cytotoxicity beyond CP55,940 or Δ(9)-THC in CB1 expressing cells. DISCUSSION: These results suggest that while some “off-targets” could possibly contribute to the SCRA toxidrome, particularly at high concentrations, CB1-mediated cellular dysfunction provides support for hypotheses concerning on-target, rather than off-target, toxicity. Further investigation of non-GPCR off-targets is warranted.
format Online
Article
Text
id pubmed-9798004
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97980042022-12-30 Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11 Kevin, Richard C. Cairns, Elizabeth A. Boyd, Rochelle Arnold, Jonathon C. Bowen, Michael T. McGregor, Iain S. Banister, Samuel D. Front Psychiatry Psychiatry INTRODUCTION: Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of new psychoactive substances that have been associated with multiple instances and types of toxicity. Some SCRAs appear to carry a greater toxicological burden than others, or compared to the prototypical cannabis-derived agonist Δ(9)-tetrahydrocannabinol (Δ(9)-THC), despite a common primary mechanism of action via cannabinoid 1 (CB1) receptors. “Off-target” (i.e., non-CB1 receptor) effects could underpin this differential toxicity, although there are limited data around the activity of SCRAs at such targets. METHODS: A selection of 7 SCRAs (AMB-FUBINACA, XLR11, PB-22, AKB-48, AB-CHMINICA, CUMYL-PINACA, and 4F-MDMB-BUTINACA), representing several distinct chemotypes and toxicological profiles, underwent a 30 μM single-point screen against 241 G protein-coupled receptor (GPCR) targets in antagonist and agonist mode using a cellular β-arrestin recruitment assay. Strong screening “hits” at specific GPCRs were followed up in detail using concentration-response assays with AMB-FUBINACA, a SCRA with a particularly notable history of toxicological liability. RESULTS: The single-point screen yielded few hits in agonist mode for any compound aside from CB1 and CB2 receptors, but many hits in antagonist mode, including a range of chemokine receptors, the oxytocin receptor, and histamine receptors. Concentration-response experiments showed that AMB-FUBINACA inhibited most off-targets only at the highest 30 μM concentration, with inhibition of only a small subset of targets, including H(1) histamine and α(2B) adrenergic receptors, at lower concentrations (≥1 μM). AMB-FUBINACA also produced concentration-dependent CB1 receptor signaling disruption at concentrations higher than 1 μM, but did not produce overt cytotoxicity beyond CP55,940 or Δ(9)-THC in CB1 expressing cells. DISCUSSION: These results suggest that while some “off-targets” could possibly contribute to the SCRA toxidrome, particularly at high concentrations, CB1-mediated cellular dysfunction provides support for hypotheses concerning on-target, rather than off-target, toxicity. Further investigation of non-GPCR off-targets is warranted. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9798004/ /pubmed/36590635 http://dx.doi.org/10.3389/fpsyt.2022.1048836 Text en Copyright © 2022 Kevin, Cairns, Boyd, Arnold, Bowen, McGregor and Banister. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Kevin, Richard C.
Cairns, Elizabeth A.
Boyd, Rochelle
Arnold, Jonathon C.
Bowen, Michael T.
McGregor, Iain S.
Banister, Samuel D.
Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11
title Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11
title_full Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11
title_fullStr Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11
title_full_unstemmed Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11
title_short Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11
title_sort off-target pharmacological profiling of synthetic cannabinoid receptor agonists including amb-fubinaca, cumyl-pinaca, pb-22, and xlr-11
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798004/
https://www.ncbi.nlm.nih.gov/pubmed/36590635
http://dx.doi.org/10.3389/fpsyt.2022.1048836
work_keys_str_mv AT kevinrichardc offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11
AT cairnselizabetha offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11
AT boydrochelle offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11
AT arnoldjonathonc offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11
AT bowenmichaelt offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11
AT mcgregoriains offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11
AT banistersamueld offtargetpharmacologicalprofilingofsyntheticcannabinoidreceptoragonistsincludingambfubinacacumylpinacapb22andxlr11